Leadership Reshuffle at Redcare Pharmacy Amid Share Price Weakness

Redcare Pharmacy appoints new supervisory board and a CFO from Amazon as its stock trades near annual lows, with leadership tasked to steer towards profitability.

Redcare Pharmacy is undergoing a significant leadership transition at both its supervisory and executive board levels, a move that comes at a challenging time for the company's stock. The changes, set for formal confirmation at the annual general meeting on April 15, 2026, will see three new supervisory board members elected and a new chief financial officer appointed.

Share Performance Under Pressure

The management overhaul coincides with a period of substantial pressure on the company's equity. The share price currently trades at its annual low, having shed approximately 71% from its 52-week high of €138.40. This market skepticism forms a difficult backdrop for the incoming leadership team.

A Renewed Supervisory Board

The supervisory board has nominated three external candidates for shareholder vote: Anja Hendel, Max Müller, and Peter Schmid von Linstow. They are slated to replace Björn Söder, Jérôme Cochet, and Jaska de Bakker. The departure of Söder and Cochet, who have served since the company's 2016 IPO, signals the close of a significant chapter.

The company expects the new appointments to bring broader strategic oversight. Hendel, most recently managing director at Volkswagen Group digital partner diconium, contributes specific expertise in digital transformation.

CFO Appointment from Amazon

A change is also occurring within the executive board. Hendrik Krampe is taking the CFO role, moving from Amazon where he served as Finance Director for the European Marketplace business since 2017. Redcare anticipates his experience in scaling digital commerce platforms will bolster its prescription (Rx) and over-the-counter (OTC) operations. He succeeds Jasper Eenhorst, who left to pursue new professional projects.

Financial Context: Growth Without Sustained Profit

This leadership transition unfolds against a mixed financial picture. For 2025, revenue increased by 24% to €2.9 billion, while adjusted EBITDA jumped 72% to about €57 million. The primary growth engine was the prescription business, where Rx revenue surpassed the €1 billion mark for the first time, aided by rising electronic prescription volume in Germany.

However, the company has yet to achieve consistent net profitability. For 2026, management is targeting an adjusted EBITDA margin of at least 2.5%. In a revision that has weighed on investor confidence, the medium-term margin target has been adjusted to 5%, down from a previously communicated 8%.

The incoming leadership thus assumes its role under considerable scrutiny. Whether this top-level restructuring can restore market faith will become clearer on May 6, 2026, when Redcare Pharmacy releases its next quarterly figures.